167834-23-3

Upstream product

• 64-17-5 ethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 83649-47-2 (S)-(-)-β-Phenyl-β-alanine hydrochloride 
• 3082-69-7 ethyl (3S)-3-amino-3-phenylpropionate 
• 121925-53-9 4-ethoxy-4-oxo-2-phenylbutanoic acid 
• 75-65-0 tert-butyl alcohol 
• 861890-42-8 ethyl (3R)-3-{[(tert-butoxy)carbonyl]amino}-2-diazo-3-phenylpropanoate 
• 150884-50-7 benzaldehyde N-boc imine 
• 100-52-7 benzaldehyde 
• 170947-99-6 C₁₈H₂₁NO₄S 
• 340188-50-3 ethyl (S)-3-amino-3-phenyl-propionate hydrochloride 
• 42201-84-3 1-ethoxy-1-(tert-butyldimethylsilyloxy)ethene 
• 177896-09-2 tert-butyl benzylidenecarbamate 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 135865-78-0 tert-butyl (1S)-3-oxo-1-phenylpropylcarbamate 
• 528586-23-4 tert-butyl ((1S)-3-oxo-1-phenylbutyl)carbamate 
• 458529-69-6 tert-butyl {(1S)-3-[methoxy(methyl)amino]-3-oxo-1-phenylpropyl}carbamate 
• 340188-50-3 ethyl (S)-3-amino-3-phenyl-propionate hydrochloride 

Relevant academic research and scientific papers

Silver-Catalyzed Enantioselective Mannich Reaction of Diazoacetate Esters with N-Boc Aldimines

The highly enantioselective Mannich reaction of diazoacetate esters with N-Boc aldimines catalyzed by silver(I) triflate in the presence of (R)-DM-SEGPHOS is reported. The reaction is broad in scope with respect to the (hetero)aromatic aldehyde-derived al

Enantioselective β-Protonation by a Cooperative Catalysis Strategy

An enantioselective N-heterocyclic carbene (NHC)-catalyzed β-protonation through the orchestration of three distinct organocatalysts has been developed. This cooperative catalyst system enhances both yield and selectivity, compared to only the NHC-catalyz

β-Amino esters from the reductive ring opening of aziridine-2-carboxylates

A general study is undertaken to examine the scope of the reductive ring opening of aziridine-2-carboxylates with samarium diiodide. The competition between C-C and C-N bond cleavage is examined as a function of the nature of the N-substituent of the aziridine, the nature of the substituent in the 3-position of the aziridine, and whether the substituent in the 3-position is in a cis or trans relationship with the carboxylate in the 2-position. The desired C-N bond cleavage leads to β-amino esters that are the predominant products for most aziridines with an N-activating group. However, C-C cleavage products are observed with an aryl group in the 3-position; this can be particularly pronounced with cis-aziridines where a nearly equal mixture of the two is observed. Exclusive formation of the C-N cleavage product is observed for all aziridines with the strongly N-activating p-toluene sulfonate group. Similarly high selectivity is observed for the 2-trimethylsilylethyl sulfonate group (SES), which is easier to remove. The utility of these methods is illustrated in the synthesis of protected forms of (R)-β3-DOPA and l-DOPA from the same aziridine, the former by SmI2-mediated reductive opening at C-2 and the latter by palladium-mediated reductive opening at C-3.

Disulfonimide-catalyzed asymmetric synthesis of β3-amino esters directly from N-Boc-amino sulfones

An asymmetric Mannich reaction of silyl ketene acetals with N-Boc-amino sulfones has been developed. A chiral disulfonimide efficiently catalyzes both the in situ generation of the corresponding N-Boc imines and the asymmetric Mannich reaction with excellent yields and enantioselectivities. Kinetic studies confirm a proposed stepwise mechanism.

Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists

Starting with a high-throughput screening lead, a novel series of CCR5 antagonists was developed utilizing an information-based approach. Improvement of pharmacokinetic properties for the series was pursued by SAR exploration of the lead template. The synthesis, SAR and biological profiles of the series are described.

1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV: Part 2

Optimisation of a series of 4-piperidinyltriazoles led to the identification of compound 28a which showed good whole cell antiviral activity, excellent selectivity over the hERG ion channel and complete oral absorption.

CHEMICAL COMPOUNDS

The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the

Substituted monocyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Organocatalytic asymmetric mannich reactions with JV-Boc and JV-Cbz protected α-amido sulfones (Boc: Tert-butoxycarbonyl, Cbz: Benzyloxycarbonyl)

Different malonates and βketoesters can react with N-tert-butoxycarbonyl- (N-Boc) and N-benzyloxycarbonyl- (N-Cbz) protected α-amido sulfones in an organocatalytic asymmetric Mannich-type reaction. The reaction makes use of a simple and easily obtained ph

TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY

The present invention provides compounds of formula (I) Wherein R1 , R2, R3 , R4 , Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors.